Study wrapper · #420
BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
Editor's note
This is a small retrospective observational cohort (328 patients, single Saudi hospital) examining BMI change with dapagliflozin, with or without weekly semaglutide, across WHO obesity classes over up to a year. Semaglutide is the secondary player here — the primary agent is the SGLT2 inhibitor dapagliflozin — and the analysis is exploratory. Researchers reported the greatest absolute BMI drop in the most severe obesity class, but proportional (percentage) change was uniform across classes, which they interpret as reflecting higher starting BMI rather than any class-specific drug advantage. The semaglutide add-on showed only a 'directional trend' toward greater benefit in one class, not a significant effect. Key limits: no control group, individual semaglutide doses were unavailable, small subgroups, and single-center scope. Read this as hypothesis-generating monitoring guidance, not evidence of semaglutide's incremental effect.
Plain-language abstract
This study looked at weight change in 328 patients at one hospital in Saudi Arabia who were prescribed the diabetes drug dapagliflozin, some also receiving weekly semaglutide, over roughly three to twelve months. The researchers grouped people by weight category and measured changes in BMI (body mass index). People in the heaviest category lost the most BMI in absolute terms, but when measured as a percentage, the change was similar across all weight groups — suggesting the bigger absolute drops simply reflected higher starting weight, not a special advantage in heavier patients. Adding semaglutide showed only a slight, non-definitive trend toward more benefit in one group. The study had no comparison group, could not access individual semaglutide doses, and involved small subgroups at a single center, so the authors describe the findings as exploratory and a basis for future, more rigorous studies. It does not clearly measure how much semaglutide itself added.